Bullfrog ai announces publication of data supporting potential of liver disease treatment candidate bf-114

Gaithersburg, md., oct. 09, 2024 (globe newswire) -- bullfrog ai holdings, inc. (nasdaq: bfrg; bfrgw) ("bullfrog ai" or the "company"), a technology-enabled drug development company using artificial intelligence (ai) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the publication of new research in the peer-reviewed journal cell reports supporting the potential of bullfrog ai's drug candidate, bf-114 (sptbn1 sirna), in treating a range of liver diseases, including metabolic dysfunction-associated steatotic liver disease (masld), metabolic dysfunction-associated steatohepatitis (mash), and hepatocellular carcinoma (hcc). the research was generated in a study led by lopa mishra, md, professor of medicine, merinoff endowed chair and co-director of the institute for bioelectronic medicine at feinstein institutes for medical research at northwell health, cold spring harbor laboratory.
BFRG Ratings Summary
BFRG Quant Ranking